American Journal of Advanced Drug Delivery
ISSN: 2321-547X

Open access Commentary

Detail Note on Liposomes as Drug Carriers

Krishna Tannure*

Department of Novel Drug Delivery, Michigan University, Germany

INTRODUCTION

Before going to the liposomes we should have an idea of drug and drug carriers. A drug is nothing but medicine or other substance which has a physiological effect when ingested or else introduced into the living body. Coming to drug carrier it was defined that any substrate used in the process of drug delivery serves to ameliorate the selectivity, effectiveness, and/ or safety of drug administration.

Liposomes were discovered about 40 times ago by Alec Bangham. A liposome is a globular vesicle having at least one lipid bilayer. They can be produced from cholesterols, non-poisonous surfactants, sphingolipids, glycolipids, long-chain adipose acids, and indeed membrane proteins.

Liposomes can be prepared by dismembering natural membranes conforming to one or further concentric spheres of the lipid bilayer are separated by waterless buffers. Considerable progress was made during the 1970s and 1980s in the field of liposome stability leading to long rotation times of liposomes. The drugs carried are loaded with a great variety of motes similar to small drug molecules, proteins, nucleotides, and indeed plasmids.

Liposomes are most frequently composed of phospholipids, especially phosphatidylcholine, but may also include other lipids, similar to egg phosphatidylethanolamine. A liposome design may employ face ligands for attaching to an unhealthy towel. In medicine delivery these are composed of fairly biocompatible and biodegradable material and they consists of an waterless volume entangled by one or further bilayers of natural or synthetic lipids.

Liposomes are micro particulate lipoid vesicles which are under expansive disquisition as medicine carriers for perfecting the delivery of remedial agents. These are composed of fairly biocompatible and biodegradable material, and they consists of an waterless volume entangled by one or further bilayers of natural or synthetic lipids. Medicines with extensively varying lipophilicities can be reprised in liposomes, either in the phospholipid bilayer or at the bilayer interface. These are physiochemically stable in-vivo and in-vitro conditions. Medicine release doesn't affect the medicine action. These are non-toxic.

- Medicines delivered complete to colourful body apkins.
- Liposomes can be used for both hydrophilic and hydrophobic medicines.
- Possibility of targeting and drop medicine toxin.
- The size, charge and other characteristics can be altered according to medicine and asked towel
- They bear numerous variations for medicine delivery to special organs.
- Stability problem and oxidative declination.
- Requires special packaging and storing installation.
- Expensive.

Optical administration of medicine is associated with the need to eyes and vision (ophthalmic conditions). Ideal ophthalmic medicine delivery system is the one which is suitable to sustain the medicine release and to remain in the vicinity of front of the eyes for prolonged period of time. Utmost of the treatments call for the topical administration of ophthalmically active medicines to towel around the optical exertion.

Deliver the medicine at a destined rate and should release the medicine at the specific point of action in the therapeutically active attention. Medicine delivery via vesicles provides dragged as well as controlled medicine delivery at the targeted corneal point. Therefore, vesicles act as prominent carrier systems. Vesicular medicine delivery systems entrap the medicine patch within lipid bilayer or surfactant vesicles.

- In the respiratory system Isoniazid and rifampicin, Cyclosporins
- As vaccine adjuvants Rabies glycoproteins, Cholera poison

During the last times, liposomes as pharmaceutical medicine carriers have entered a lot of attention. The new developments

Received:	03-January-2022	**Manuscript No:**	ipaad-22-12383
Editor assigned:	05-January-2022	**PreQC No:**	ipaad-22-12383 (PQ)
Reviewed:	19-January-2022	**QC No:**	ipaad-22-12383
Revised:	24-January-2022	**Manuscript No:**	ipaad-22-12383 (R)
Published:	31-January-2022	**DOI:**	10.36648/2321-547X.21.9.01

Corresponding author Krishna Tannure, Department of Novel Drug Delivery, Michigan University, Germany, E-mail: krishna91_pharmacy@yahoo.com

Citation Krishna T (2022) Detail note on liposomes as drug carriers. Am J Adv Drug Deliv. 10:001.

with liposomes are nonstop process which helps for better targeting with lower toxin. Some commercially available liposomes in the request include Mikasome, Daunaxome, Verteporfin.

ACKNOWLEDGEMENT

The author is grateful to all the research and scientific community in helping him to publish his article.

CONFLICT OF INTEREST

There is no conflict of interests whatsoever in publishing this article.